Ung Lawson, Chua Terence C, Morris David L
UNSW Department of Surgery, St George Clinical School, Kogarah, New South Wales, Australia.
ANZ J Surg. 2013 Nov;83(11):821-6. doi: 10.1111/ans.12306. Epub 2013 Jul 1.
There is now a considerable body of published evidence supporting the use of a multimodal approach consisting of cytoreductive surgery (CS) and heated intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal metastases (PM) arising from selected gastrointestinal tract malignancies. In the absence of systemic metastases, it is thought that disease confined to the peritoneum may be eradicated through optimum cytoreduction. This review critically evaluates the current body of published evidence for the use of CS/HIPEC in the treatment of advanced colorectal, appendiceal and gastric cancer. Although its role remains less defined in patients with gastric PM, current evidence provides a compelling argument for its use in PM of colorectal and appendiceal origin. With a low mortality and acceptable morbidity rate, CS/HIPEC may offer hope of long-term survival and cure in a defined group of patients with this disease.
目前已有大量已发表的证据支持采用由细胞减灭术（CS）和热灌注化疗（HIPEC）组成的多模式方法来治疗特定胃肠道恶性肿瘤引起的腹膜转移（PM）。在没有全身转移的情况下，人们认为局限于腹膜的疾病可通过最佳的细胞减灭术得以根除。本综述批判性地评估了目前已发表的关于CS/HIPEC用于治疗晚期结直肠癌、阑尾癌和胃癌的证据。尽管其在胃癌腹膜转移患者中的作用仍不太明确，但目前的证据有力地支持了其在结直肠癌和阑尾癌来源的腹膜转移中的应用。CS/HIPEC死亡率低且发病率可接受，可能为特定组别的此类疾病患者带来长期生存和治愈的希望。
